In a word...validation. That is what we need.
Post# of 153864
(Total Views: 456)
Posted On: 03/03/2020 4:46:50 PM
In a word...validation.
That is what we need. We have the validation when it comes to the science. There are so many peer reviewed articles on CCR5 antagonists. At this point, I don't think any on this board doubt the science.
But I do think we need validation when it comes to us being able to get a product to market. We have had a little (i.e. Samsung, Vyera) but we clearly need more.
When I first hopped on board the CYDY train, I thought, "I can't believe it...I got in this before it took off...this never happens to me" but you quickly realize that this is a strange beast. There have been many missed deadlines and lots of different paths pursued. There have been dramatic hires and even more dramatic departures. We are atypical compared to most biotechs at our stage and while we can debate whether that is good or bad (as we do most days on this board), the fact is that marching to the beat of our own drum does feed into the skeptics.
In my opinion this will eventually work out very well for all of us but we really could use some validation in the form of a BTD, BLA approval, BP deal, outside investment....just some other large entity putting their neck on the line to say "we have kicked the tires and checked under the hood and this is as good as we all think it is" Crossing my fingers we get a clear path this Thursday.
That is what we need. We have the validation when it comes to the science. There are so many peer reviewed articles on CCR5 antagonists. At this point, I don't think any on this board doubt the science.
But I do think we need validation when it comes to us being able to get a product to market. We have had a little (i.e. Samsung, Vyera) but we clearly need more.
When I first hopped on board the CYDY train, I thought, "I can't believe it...I got in this before it took off...this never happens to me" but you quickly realize that this is a strange beast. There have been many missed deadlines and lots of different paths pursued. There have been dramatic hires and even more dramatic departures. We are atypical compared to most biotechs at our stage and while we can debate whether that is good or bad (as we do most days on this board), the fact is that marching to the beat of our own drum does feed into the skeptics.
In my opinion this will eventually work out very well for all of us but we really could use some validation in the form of a BTD, BLA approval, BP deal, outside investment....just some other large entity putting their neck on the line to say "we have kicked the tires and checked under the hood and this is as good as we all think it is" Crossing my fingers we get a clear path this Thursday.
(2)
(0)